Arrowhead Pharmaceuticals, Inc.
RNAi Inhibition of Alpha-ENaC Expression
Last updated:
Abstract:
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
Status:
Application
Type:
Utility
Filling date:
23 Dec 2021
Issue date:
14 Apr 2022